Echelon Biosciences, Lumiphore In Licensing Agreement
Salt Lake City, Utah-based Echelon Biosciences said this week that it has finalized a license agreement with Lumiphore to use its technology for the development of cancer assays. Echelon said that it would have access to Lumiphore's lanthanide-complex technology, used for research and drug discovery. The technology is useful in new drug development for cancer, diabetes, and inflammation. Financial terms were not disclosed.
posted on Wednesday, April 5, 2006
Related companies:
Echelon Biosciences
Related stories:
> Frontier Scientific Acquires Echelon Biosciences
> Numira Biosciences Buys Firm
> First Data, PrivaSys Agree to Licensing Deal
> DISH, Rovi In Patent Licensing Deal
> Numira Biosciences Adds To Board
Techrockies.com Home